Cassava Sciences (SAVA) 10-K 18 Feb 15 2014 FY Annual report Financial data

Document_And_Entity_Informatio

Document And Entity Information (USD $)	12 Months Ended
	Dec. 31, 2014	Jan. 12, 2015	Jun. 30, 2014
Document And Entity Information [Abstract]
Document Type	10-K
Amendment Flag	FALSE
Document Period End Date	31-Dec-14
Document Fiscal Year Focus	2014
Document Fiscal Period Focus	FY
Trading Symbol	PTIE
Entity Registrant Name	PAIN THERAPEUTICS INC
Entity Central Index Key	1069530
Current Fiscal Year End Date	-19
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		45,756,117
Entity Public Float			$219,561,715
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No

Balance_Sheets

Balance Sheets (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Current assets:
Cash and cash equivalents	$40,590	$48,588
Marketable securities		1,250
Other current assets	239	265
Total current assets	40,829	50,103
Property and equipment, net	65
Other assets	12
Total assets	40,906	50,103
Current liabilities:
Accounts payable	173	445
Accrued development expense	25	641
Accrued compensation and benefits	652	712
Other current liabilities		3
Total current liabilities	850	1,801
Total liabilities	850	1,801
Commitments and contingencies
Stockholders' equity:
Preferred stock, $.001 par value; 10,000,000 shares authorized, none issued and outstanding
Common stock, $.001 par value; 120,000,000 shares authorized; 45,756,117 and 45,510,038 shares issued and outstanding at December 31, 2014 and 2013, respectively	46	45
Additional paid-in capital	156,502	152,363
Accumulated other comprehensive income	1	1
Accumulated deficit	-116,493	-104,107
Total stockholders' equity	40,056	48,302
Total liabilities and stockholders' equity	$40,906	$50,103

Balance_Sheets_Parenthetical

Balance Sheets (Parenthetical) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Balance Sheets [Abstract]
Preferred stock, par value	$0.00	$0.00
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$0.00	$0.00
Common stock, shares authorized	120,000,000	120,000,000
Common stock, shares issued	45,756,117	45,510,038
Common stock, shares outstanding	45,756,117	45,510,038

Statements_Of_Operations

Statements Of Operations (USD $)	12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Revenue:
Program fee revenue		$41,119	$10,641
Collaboration revenue			249
Total revenue		41,119	10,890
Operating expenses:
Research and development	7,306	4,917	7,605
General and administrative	5,127	4,837	7,182
Total operating expenses	12,433	9,754	14,787
Operating income (loss)	-12,433	31,365	-3,897
Interest income	47	106	451
Income (loss) before provision for (benefit from) income taxes	-12,386	31,471	-3,446
Provision for (benefit from) income taxes		-73
Net income (loss)	($12,386)	$31,544	($3,446)
Net income (loss) per share
Basic	($0.27)	$0.70	($0.08)
Diluted	($0.27)	$0.70	($0.08)
Weighted-average shares used in computing net income (loss) per share
Basic	45,269	45,007	44,753
Diluted	45,269	45,208	44,753

Statements_Of_Comprehensive_In

Statements Of Comprehensive Income (Loss) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Statements Of Comprehensive Income (Loss) [Abstract]
Net income (loss)	($12,386)	$31,544	($3,446)
Other comprehensive losses:
Net unrealized losses on marketable securities		-3	-124
Comprehensive income (loss)	($12,386)	$31,541	($3,570)

Statements_Of_Stockholders_Equ

Statements Of Stockholders' Equity (USD $)	Common Stock [Member]	Additional Paid-In Capital [Member]	Accumulated Other Comprehensive Income [Member]	Accumulated Deficit [Member]	Total
In Thousands, except Share data
Balance at Dec. 31, 2011	$45	$176,425	$128	($132,205)	$44,393
Balance, Shares at Dec. 31, 2011	44,732,017
Issuance of common stock pursuant to exercise of stock options and awards, net of taxes paid on net issuance of stock options and awards		-366			-366
Issuance of common stock pursuant to exercise of stock options and awards, net of taxes paid on net issuance of stock options and awards, shares	574,370
Issuance of common stock related to employee stock purchase plan		64			64
Issuance of common stock related to employee stock purchase plan, shares	20,553
Compensation with respect to non-employee option grants		75			75
Compensation with respect to employee option grants and share based awards		6,535			6,535
Non-dividend cash distribution of $0.75 per share		-33,995			-33,995
Other comprehensive loss			-124		-124
Net income (loss)				-3,446	-3,446
Balance at Dec. 31, 2012	45	148,738	4	-135,651	13,136
Balance, Shares at Dec. 31, 2012	45,326,940
Issuance of common stock pursuant to exercise of stock options and awards, net of taxes paid on net issuance of stock options and awards		492			492
Issuance of common stock pursuant to exercise of stock options and awards, net of taxes paid on net issuance of stock options and awards, shares	166,635
Issuance of common stock related to employee stock purchase plan		32			32
Issuance of common stock related to employee stock purchase plan, shares	16,463
Compensation with respect to non-employee option grants		95			95
Compensation with respect to employee option grants and share based awards		3,006			3,006
Other comprehensive loss			-3		-3
Net income (loss)				31,544	31,544
Balance at Dec. 31, 2013	45	152,363	1	-104,107	48,302
Balance, Shares at Dec. 31, 2013	45,510,038
Issuance of common stock pursuant to exercise of stock options	1	378			379
Issuance of common stock pursuant to exercise of stock options, shares	246,079				1,245,750
Compensation with respect to non-employee option grants		142			142
Compensation with respect to employee option grants		3,619			3,619
Net income (loss)				-12,386	-12,386
Balance at Dec. 31, 2014	$46	$156,502	$1	($116,493)	$40,056
Balance, Shares at Dec. 31, 2014	45,756,117

Statements_Of_Stockholders_Equ1

Statements Of Stockholders' Equity (Parenthetical) (USD $)	12 Months Ended
	Dec. 31, 2012
Statements Of Stockholders' Equity [Abstract]
Non-dividend cash distribution, per share	$0.75

Statements_Of_Cash_Flows

Statements Of Cash Flows (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Cash flows used in operating activities:
Net income (loss)	($12,386)	$31,544	($3,446)
Adjustments to reconcile net income (loss) to net cash used in operating activities:
Deferred program fee revenue		-41,119	-10,641
Non-cash stock based compensation	3,761	3,101	6,610
Depreciation and amortization	15		122
Non-cash net interest income	-2	-10	342
Changes in operating assets and liabilities:
Other current assets	26	-12	105
Other non-current assets	-12	352
Accounts payable	-272	84	-103
Accrued development expense	-616	-288	15
Accrued compensation and benefits	-60	-141	-62
Excess tax benefits from equity-based compensation plans			-57
Other current liabilities	-3	-21	-58
Deferred tax liabilities		-437	2
Net cash used in operating activities	-9,549	-6,947	-7,171
Cash flows provided by investing activities:
Purchases of property and equipment	-80
Purchases of marketable securities	-2,598	-6,644	-20,768
Maturities of marketable securities	3,850	12,300	38,390
Net cash provided by investing activities	1,172	5,656	17,622
Cash flows provided by (used in) financing activities:
Nondividend distribution			-33,995
Excess tax benefits from equity-based compensation plans			57
Proceeds from issuance of common stock, net	379	524	-302
Net cash provided by (used in) financing activities	379	524	-34,240
Net decrease in cash and cash equivalents	-7,998	-767	-23,789
Cash and cash equivalents at beginning of the period	48,588	49,355	73,144
Cash and cash equivalents at end of the period	$40,590	$48,588	$49,355

General

General	12 Months Ended
	Dec. 31, 2014
General [Abstract]
General	1.  General
	We are a biopharmaceutical company that develops novel drugs. Our lead drug candidate, REMOXY, is an extended-release oral formulation of oxycodone for the management of moderate-to-severe pain when a continuous, around-the-clock opioid analgesic is needed for an extended period of time. We designed REMOXY to discourage common methods of tampering and misuse.
	In the course of our development activities, we have sustained cumulative operating losses. There are no assurances that additional financing will be available on favorable terms, or at all.

Summary_Of_Significant_Account

Summary Of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2014
Summary Of Significant Accounting Policies [Abstract]
Summary Of Significant Accounting Policies	2.  Summary of Significant Accounting Policies
	Use of Estimates
	The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires that management make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of revenue earned and expenses incurred during the reporting period. Actual results could differ from those estimates.
	Revenue Recognition and Deferred Program Fee Revenue
	Revenue is recognized when there is persuasive evidence that an arrangement exists, delivery has occurred, the price is fixed or determinable, and collection is reasonably assured.
	We have recognized program fee revenue, collaboration revenue and milestone revenue under the Collaboration Agreement and License Agreement with Pfizer, or the Pfizer Agreements. Program fee revenue was derived from upfront payments from Pfizer. Through the end of the third quarter of 2013, these payments were recognized from receipt ratably over our estimate of the development period under the Pfizer Agreements. In October 2013, we and Pfizer amended the Pfizer Agreements, we no longer had any substantive responsibilities for development activities under the Pfizer Agreements and, during the fourth quarter of 2013, we recognized all remaining deferred program fee revenue as program fee revenue.
	Collaboration revenues from reimbursement of development expenses was generally recognized when Pfizer completed its review of the expenses invoiced to them.
	We recognized milestone payments from Pfizer as revenue when we achieved the underlying developmental milestone as the milestone payments were not dependent upon any other future activities or achievement of any other future milestones and the achievement of each of the developmental milestones were substantively at risk and contingent at the effective date of the collaboration. Substantial effort was involved in achieving each of the developmental milestones. These milestones represented the culmination of discrete earnings processes and the amount of each milestone payment was reasonable in relation with the level of effort associated with the achievement of the milestone. Each milestone payment was non-refundable and non-creditable when made. Research and development services provided under the Pfizer Agreements were priced at fair value based upon the reimbursement of expenses incurred pursuant to the Pfizer Agreements.
	Cash, Cash Equivalents and Concentration of Credit Risk
	We consider all highly liquid financial instruments with original maturities of three months or less to be cash equivalents. Cash and cash equivalents are maintained at two financial institutions and in money market funds. We believe the financial risks associated with these instruments are minimal. We have not incurred material losses from our investments in these securities.
	Marketable Securities and Fair Value Measurements
	We invest in interest-bearing marketable securities, generally consisting of corporate and government securities. We may elect to sell these investments before they mature. Therefore, we hold these investments as “available for sale” and include these investments in our balance sheets as current assets, even though the contractual maturity of a particular investment may be beyond one year. We report our marketable securities at fair value, which may include unrealized gains and losses. Our unrealized gains and losses on investments are recorded as a separate component of stockholders’ equity as accumulated other comprehensive income or loss. We recognize all realized gains and losses on our available-for-sale securities in interest income in the accompanying statement of operations on a specific identification basis. Our marketable securities are maintained at one financial institution and are governed by our investment policy as approved by our Board of Directors.
	To date we have not recorded any impairment charges on marketable securities related to other-than-temporary declines in market value. We would recognize an impairment charge when the decline in the estimated fair value of a marketable security below the amortized cost is determined to be other-than-temporary. We consider various factors in determining whether to recognize an impairment charge, including the duration of time and the severity to which the fair value has been less than our amortized cost, any adverse changes in the investees’ financial condition and our intent to sell or whether it is more likely than not that we would be required to sell the marketable security before its anticipated recovery.
	We measure our cash equivalents and marketable securities at fair value on a recurring basis and have significant observable inputs where there are identical or comparable assets in the market to use in establishing our fair value measurements. We use significant observable inputs that include but are not limited to benchmark yields, reported trades, broker/dealer quotes and issuer spreads. We consider these inputs to be Level 2 inputs. Generally, the types of instruments we invest in are not traded on a market such as the NASDAQ Global Market, which we would consider to be Level 1 inputs. We do not have any investments that would require inputs considered to be Level 3. We use the bid price to establish fair value.
	Business Segments
	We report segment information based on how we internally evaluate the operating performance of our business units, or segments. Our operations are confined to one business segment: the development of novel drugs.
	Stock-based Compensation
	We recognize non-cash expense in the statement of operations for the fair value of all share-based payments, including grants of employee stock options and other share based awards. For stock options, we use the Black-Scholes option valuation model and the single-option award approach and straight-line attribution method. Using this approach, the compensation expense is amortized on a straight-line basis over the vesting period of each respective stock option, generally four years.
	We have granted share-based awards that vest upon achievement of certain performance criteria, or Performance Awards. The value of these awards is the product of the number of shares of our common stock to be issued under the award multiplied by the fair market value of a share of our common stock on the date of grant. These awards include future performance conditions. We estimate an implicit service period for achieving these performance conditions. Performance Awards vest and common stock is issued on achieving performance conditions. We recognize non-cash stock-based compensation expense for Performance Awards when we conclude that achieving a performance condition is probable. We periodically review and update as appropriate our estimates of the implicit service periods and the likelihood of achieving the performance conditions.
	Net Loss per Share
	Basic net loss per share is computed on the basis of the weighted-average number of common shares outstanding for the reporting period. Diluted net loss per share is computed on the basis of the weighted-average number of common shares outstanding plus dilutive potential common shares outstanding using the treasury-stock method. Potential dilutive common shares consist of outstanding stock options and warrants. The numerators and denominators in the calculation of basic and diluted net loss per share were as follows (in thousands):
		Years ended December 31,
		2014		2013		2012
	Numerator:
	Net income (loss)	$	-12,386	$	31,544	$	-3,446
	Denominator:
	Weighted-average shares used to compute basic net income (loss) per share		45,269		45,007		44,753
	Effect of dilutive securities - Dilution from employee stock plans		—		201		—
	Weighted-average shares used to compute diluted net income (loss) per share		45,269		45,208	—	44,753
	Net income (loss) per share - Basic	$	-0.27	$	0.70	$	-0.08
	Net income (loss) per share - Diluted	$	-0.27	$	0.70	$	-0.08
	We excluded weighted options outstanding to purchase common stock of 10.6 million for 2014, 13.5 million for 2013 and 13.2 million for 2012 from the calculation of diluted net loss per share because the effect of including these shares in this calculation would be anti-dilutive.
	Income Taxes
	We make estimates and judgments in determining the need for a provision for income taxes, including the estimation of our taxable income or loss for each full fiscal year. We have accumulated significant deferred tax assets. Deferred income taxes reflect the tax effects of net operating loss and tax credit carryovers and temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Realization of certain deferred tax assets is dependent upon future earnings, if any. We are uncertain about the timing and amount of any future earnings. Accordingly, we offset these net deferred tax assets with a valuation allowance. We may in the future determine that our deferred tax assets will likely be realized, in which case we will reduce our valuation allowance in the quarter in which such determination is made. If the valuation allowance is reduced, we may recognize a benefit from income taxes in our statement of operations in that period. We classify interest and penalties recognized related to uncertain tax positions as interest expense.
	Recent Accounting Pronouncements
	We reviewed recently issued accounting pronouncements and plan to adopt those that are applicable to us. We do not expect the adoption of these pronouncements to have a material impact on our financial position, results of operations or cash flows.

Collaboration_Agreements

Collaboration Agreements	12 Months Ended
	Dec. 31, 2014
Collaboration Agreements [Abstract]
Collaboration Agreements	3.  Collaboration Agreements
	Pfizer, Inc.
	Pfizer conducted development of REMOXY pursuant to the Pfizer Agreements. We received a $150.0 million upfront fee in connection with the closing of the Pfizer Agreements and $5.0 million in July 2010 in connection with an amendment to the Pfizer Agreements. As of December 31, 2013, all of these payments had been recognized as program fee revenue, including $41.1 million in 2013 and $10.6 million in 2012. In addition, Pfizer funded development expenses incurred by us pursuant to the Pfizer Agreements, of which we recorded as collaboration revenue $0.2 million in 2012.
	On October 26, 2014, Pfizer provided us with written notice of termination of our Collaboration Agreement with Pfizer. Pursuant to the terms of the Collaboration Agreement, the effective date of termination of the Collaboration Agreement is six months from October 26, 2014. The terms of our License Agreement with Pfizer provide that such agreement terminates automatically upon termination of the Collaboration Agreement.
	Durect Corporation
	We have an exclusive, worldwide licensing agreement with Durect Corporation to use a patented technology that forms the basis for certain drug candidates, including REMOXY. Under the agreement with Durect, we control all of the preclinical, clinical, commercial manufacturing and sales/marketing activities for REMOXY and other abuse-resistant opioid painkillers. We reimburse Durect for formulation and related work, and will make milestone payments based on the achievement of certain technical, clinical or regulatory milestones. We also are responsible to pay Durect royalties on any related drug sales.

Cash_And_Cash_Equivalents_And_

Cash And Cash Equivalents And Marketable Securities	12 Months Ended
	Dec. 31, 2014
Cash And Cash Equivalents And Marketable Securities [Abstract]
Cash And Cash Equivalents And Marketable Securities	4.  Cash and Cash Equivalents and Marketable Securities
	Cash, cash equivalents and marketable securities held as available-for-sale consisted of the following (in thousands):
			Cash, Cash Equivalents and Marketable Securities
			Amortized Cost		Unrealized Gains		Unrealized Losses		Estimated Fair Value		Accrued Interest		Total Value
		31-Dec-14
		Cash	$	295	$	—	$	—	$	295	$	—	$	295
		Cash equivalents		34,805		—		—		34,805		—		34,805
		Commercial paper		4,848		1		—		4,849		—		4,849
		Corporate securities		631		—		—		631		10		641
			$	40,579	$	1	$	—	$	40,580	$	10	$	40,590
		Reported as:
		Cash and cash equivalents	$	40,579	$	1	$	—	$	40,580	$	10	$	40,590
			$	40,579	$	1	$	—	$	40,580	$	10	$	40,590
		Maturities:
		Matures in one year or less	$	40,579	$	1	$	—	$	40,580	$	10	$	40,590
		Matures one to three years		—		—		—		—		—		—
			$	40,579	$	1	$	—	$	40,580	$	10	$	40,590
		31-Dec-13
		Cash and cash equivalents	$	48,587	$	1	$	—	$	48,588	$	—	$	48,588
		Commercial paper		1,250		—		—		1,250		—		1,250
			$	49,837	$	1	$	—	$	49,838	$	—	$	49,838
		Reported as:
		Cash and cash equivalents	$	48,587	$	1	$	—	$	48,588	$	—	$	48,588
		Marketable securities		1,250		—		—		1,250		—		1,250
			$	49,837	$	1	$	—	$	49,838	$	—	$	49,838
		Maturities:
		Matures in one year or less	$	49,837	$	1	$	—	$	49,838	$	—	$	49,838
		Matures one to three years		—		—		—		—		—		—
			$	49,837	$	1	$	—	$	49,838	$	—	$	49,838
	To date we have not recorded any impairment charges on marketable securities related to other-than-temporary declines in market value.
	Our assets measured at fair value were (in thousands):
			Level 1		Level 2		Level 3		Total
		31-Dec-14
		Cash and cash equivalents	$	35,100	$	—	$	—	$	35,100
		Commercial paper		—		4,849		—		4,849
		Corporate securities		—		641		—		641
			$	35,100	$	5,490	$	—	$	40,590
		31-Dec-13
		Cash and cash equivalents	$	48,588	$	—	$	—	$	48,588
		Commercial paper		—		1,250		—		1,250
			$	48,588	$	1,250	$	—	$	49,838

Property_And_Equipment

Property And Equipment	12 Months Ended
	Dec. 31, 2014
Property And Equipment [Abstract]
Property And Equipment
	5.  Property and Equipment
	Property and equipment includes furniture and equipment with a purchase value of $0.7 million at December 31, 2014 and $0.6 million at December 31, 2013. Depreciation is recognized using the straight-line method over the expected life of the property and equipment. Accumulated depreciation was $0.6 million at December 31, 2014 and 2013. Depreciation and amortization expense was immaterial in 2014 and 2013 and $0.1 million in 2012.

Stockholders_Equity_And_StockB

Stockholders' Equity And Stock-Based Compensation	12 Months Ended
	Dec. 31, 2014
Stockholders' Equity And Stock-Based Compensation [Abstract]
Stockholders' Equity And Stock-Based Compensation	6.  Stockholders' Equity and Stock-Based Compensation
	Preferred Stock
	Our Board of Directors has the authority to issue preferred stock in one or more series and to fix the rights, preferences, privileges, restrictions and the number of shares constituting any series or the designation of the series.
	We have a stockholder rights plan, or the Rights Plan, designed to guard against partial tender offers and other coercive tactics to gain control of the Company without offering a fair and adequate price and terms to all of the Company’s stockholders. Pursuant to the Rights Plan, our Board of Directors declared and paid a dividend of one right to purchase one one-thousandth share of our Series A Participating Preferred Stock for each outstanding share of our common stock. Each of these rights entitles the registered holder to purchase from us one one-thousandth of a share of Series A Preferred at an exercise price of $40.00, subject to adjustment at any time.
	2008 Equity Incentive Plan
	Under our 2008 Equity Incentive Plan, or 2008 Equity Plan, our employees, directors and consultants may receive share-based awards, including grants of stock options and Performance Awards. Our Board of Directors or a designated Committee of the Board is responsible for administration of the 2008 Equity Plan and determines the terms and conditions of each option granted, consistent with the terms of the plan.
	Stock options generally expire ten years from the date of grant. Cancelled share-based awards become available for reissuance. Shares reserved for issuance and available for grant under the 2008 Equity Incentive Plan were 4.1 million as of December 31, 2014. The 2008 Equity Plan terminates in 2018.
	The 2008 Equity Plan provides for the automatic grant of options to purchase shares of common stock to outside directors. On the date of each annual stockholders’ meeting, each outside director is automatically granted an option to purchase 50,000 shares of common stock. These options have a ten-year life, have an exercise price of 100% of the fair market value of the stock on the date of grant, and become exercisable as to 25% of the shares on the anniversary of its date of grant provided the optionee continues to serve as a director on such dates.
	When stock options or Performance Awards are exercised net of the exercise price and taxes, the number of shares of stock issued is reduced by the number of shares equal to the amount of taxes owed by the award recipient and that number of shares are cancelled and returned to the 2008 Equity Plan. We then use our cash to pay tax authorities the amount of statutory taxes owed by and on behalf of the award recipient.
	Stock Options
	The following summarizes information about stock option activity during 2014:
			Number of Options		Weighted Average Exercise Price		Weighted Average Remaining Contractual Term		Aggregate Intrinsic Value
							In years			In millions
		Outstanding as of December 31, 2013	16,133,893		$	4.06	5		$	16.3
		Granted	3,525,000		$	3.45
		Exercised	-1,245,750		$	4.52
		Cancelled	-499,961		$	3.84
		Outstanding as of December 31, 2014	17,913,182		$	3.92	5		$	0.5
		Vested and expected to vest at December 31, 2014	17,913,182		$	3.92	5		$	0.5
		Exercisable at December 31, 2014	13,132,300		$	4.17	3.5		$	0
	The pre-tax intrinsic value of options exercised,  calculated by multiplying options exercised by the difference between our stock price on the date of exercise and the exercise price of the options, was approximately $0.9 million in 2014, $0.2 million in 2013 and immaterial in 2012.
	The following summarizes information about stock options outstanding at December 31, 2014 by a range of exercise prices:
							Options outstanding						Options exercisable
									Weighted
									average		Weighted			Weighted
							Number of		remaining		average		Number of	average
		Range of exercise prices					outstanding		contractual		exercise		vested	exercise
		From			To		options		life (in years)		price		options	price
		$	1.72		$	2.58	4,582,503		7.5		$	2.21	2,006,262	$	2.51
		$	2.8		$	3.41	4,370,573		4.1		$	3.22	3,832,495	$	3.23
		$	3.58		$	4.82	4,320,069		3.2		$	4.59	4,059,038	$	4.59
		$	4.88		$	7	3,695,188		5		$	5.13	2,387,711	$	5.15
		$	7.65		$	7.65	944,849		5.5		$	7.65	846,794	$	7.65
							17,913,182		5		$	3.92	13,132,300	$	4.17
	We use Black-Scholes to estimate the fair value of options granted. Black-Scholes considers a number of factors, including the market price of our common stock. For options granted to employees and directors, we used certain factors to value each stock option granted, which resulted in a weighted average fair value of options granted during 2014, 2013 and 2012, as follows:
		2014		2013		2012
	Volatility	68% to 74%		58% to 64%		56% to 64%
	Risk-free interest rates	1% to 2%		1% to 2%		1%
	Expected life of option	7 years		7 years		6 years
	Dividend yield	zero		zero		zero
	Forfeiture rate	zero		zero		7%
	Weighted average fair value of stock options granted	$2.32		$1.54		$1.70
	Volatility is based on reviews of the historical volatility of our common stock. Risk-free interest rates are based on yields of U.S. treasury notes in effect at the date of grant. Expected life of option is based on actual historical option exercises. Dividend yield is zero because we do not anticipate paying cash dividends in the foreseeable future. We estimate forfeitures and adjust this estimate periodically based in part on the extent to which actual forfeitures differ from our estimates.
	For options granted to non-employees, we estimate the fair value of stock options granted using factors similar to those used for stock options granted to employees and directors and appropriate for the terms underlying the stock options granted to non-employees. We re-measure the compensation expense for options granted to non-employees each reporting period.
	As of December 31, 2014, we expect to recognize compensation expense of $10.3 million related to non-vested options over the weighted average remaining recognition period of 3.0 years.
	Performance Awards
	The following summarizes information about Performance Award activity during 2014:
									Number of Performance Awards
	Outstanding as of December 31, 2013								3,250,065
	Granted								885,000
	Cancelled								-2,245,600
	Outstanding as of December 31, 2014								1,889,465
	No outstanding Performance Awards are vested. If and when outstanding Performance Awards vest, we would recognize $5.3 million in non-cash stock-based compensation expense. These Performance Awards expire between in 2022 and 2024.
	2000 Employee Stock Purchase Plan
	Prior to 2014, certain employees purchased common stock  under our amended and restated 2000 Employee Stock Purchase Plan, or the Purchase Plan, within the statutory limits under Internal Revenue Service regulations. The purchase price of the stock purchased under the Purchase Plan was 85% of the lower of the fair market value of the common stock at the beginning of the offering period or at the end of the purchase period. We use Black-Scholes to estimate the fair value of rights granted under the Purchase Plan, using assumptions similar to those used in determining the fair value of options. No stock was purchased under the Purchase Plan in 2014. Stock-based compensation expense related to the Purchase Plan was immaterial in 2014.
	Stock-Based Compensation Expense
	The following summarizes information about non-cash stock-based compensation expense, in thousands:
		Years ended December 31,
		2014			2013		2012
	Research and development	$	1,624		$	1,349	$	3,164
	General and administrative		2,137			1,752		3,446
		$	3,761		$	3,101	$	6,610

Employee_401k_Benefit_Plan

Employee 401(k) Benefit Plan	12 Months Ended
	Dec. 31, 2014
Employee 401(k) Benefit Plan [Abstract]
Employee 401(k) Benefit Plan	7.  Employee 401(k) Benefit Plan
	We have a defined-contribution savings plan under Section 401(k) of the Internal Revenue Code. The plan covers substantially all employees. Employees are eligible to participate in the plan the first day of the month after hire and may contribute up to the current statutory limits under Internal Revenue Service regulations. The 401(k) plan permits us to make additional matching contributions on behalf of all employees. Through December 31, 2014, we have not made any matching contributions to the 401(k) plan.

Income_Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2014
Income Taxes [Abstract]
Income Taxes	8.  Income Taxes
	We did not provide for income taxes in 2014 and 2012 because we had a net operating loss for tax purposes in those years and the tax benefit that would have resulted from the statutory rate was fully offset by the valuation allowance. We recorded a non-cash benefit from income taxes in 2013 related to previously unrecognized tax benefits for use of certain research and development tax credits in 2006. Other than this benefit, we did not provide for income taxes in 2013 because we had a net operating loss for tax purposes in 2013. A reconciliation between the amount computed by multiplying our income before benefit from income taxes for 2013 by the U.S. statutory tax rate and our benefit from income taxes follows (in thousands):
						2013
	Tax at U.S. statutory tax rate of 34%					$	10,725
	State taxes						-73
	Equity-based compensation						844
	Research credits						-81
	Other						-242
	Change in valuation allowance						-11,246
	Benefit from income taxes					$	-73
	Deferred tax assets and valuation allowance
	Deferred tax assets reflect the tax effects of net operating loss and tax credit carryforwards and temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of our deferred tax assets are as follows (in thousands):
		December 31,
		2014		2013
	Deferred tax assets:
	Net operating loss carryforwards	$	13,800	$	10,200
	Stock-related compensation		10,900		11,100
	Research & development credit carryforwards		5,800		5,700
	Other		300		600
			30,800		27,600
	Valuation allowance		-30,800		-27,600
		$	—	$	—
	We are uncertain about the timing and amount of any future profits. Accordingly, we offset our deferred tax assets by a valuation allowance. The valuation allowance increased by $3.2 million in 2014 and decreased by $14.6 in 2013.
	Our pre-tax net operating loss carryforwards of $43.0 million are federal and expire between 2029 and 2034.  Our deferred tax assets exclude certain federal tax deductions associated with stock option transactions over and above the stock related compensation expenses in our financial statements by approximately $2.5 million. If and when we are able to reduce our income taxes payable with these tax deductions, we will credit additional paid-in capital.
	As of December 31, 2014, we had federal research and development tax credits of approximately $9.7 million, which expire in the years 2023 through 2034.
	Unrecognized tax benefits
	We have unrecognized tax benefits related primarily to tax credits. In 2013, we reduced our unrecognized tax benefits for the lapse of applicable statute of limitations for tax credits used in prior years. A reconciliation of the beginning and ending unrecognized tax benefits recorded for 2014, 2013 and 2012 follows (in thousands):
			2014		2013
	Beginning balance	$	3,800	$	5,200
	Additions based on tax positions related to the current year		100		100
	Lapse of applicable statute of limitations		—		-600
	Reductions for tax positions related to prior years		—		-900
	Ending balance	$	3,900	$	3,800

Leases_And_Commitments

Leases And Commitments	12 Months Ended
	Dec. 31, 2014
Leases And Commitments [Abstract]
Leases And Commitments	9.  Leases and Commitments
	We lease approximately 6,000 square feet of office space pursuant to a non-cancelable operating lease in Austin, TX that expires in 2017.  Future minimum lease payments are as follows for the years ended December 31, (in thousands):
		2015		2016		2017		Total
	Minimum lease payments	$	143	$	146	$	147	$	436
	We believe that our facilities are adequate and suitable for our current needs. Rent expense was $0.1 million in 2014,  2013 and 2012.
	We conduct our product research and development programs through a combination of internal and collaborative programs that include, among others, arrangements with universities, contract research organizations and clinical research sites. We have contractual arrangements with these organizations, however these contracts are cancelable on thirty days’ notice and our obligations under these contracts are largely based on services performed.

Legal_Proceedings

Legal Proceedings	12 Months Ended
	Dec. 31, 2014
Legal Proceedings [Abstract]
Legal Proceedings	10.  Legal proceedings
	K B Partners I, L.P., Individually and On Behalf of All Others Similarly Situated v. Pain Therapeutics, Inc., Remi Barbier, Nadav Friedmann and Peter S. Roddy.
	On December 2, 2011, a purported class action was filed against us and our executive officers in the U.S. District Court for the Western District of Texas. This complaint alleges, among other things, violations of Section 10(b), Rule 10b-5, and Section 20(a) of the Exchange Act arising out of allegedly untrue or misleading statements of material facts made by us regarding REMOXY’s development and regulatory status during the purported class period, February 3, 2011 through June 23, 2011. The complaint states that monetary damages are being sought, but no amounts are specified. On June 3, 2013, the Court certified a class consisting of all purchasers of our common stock and a class period of December 27, 2010 through June 26, 2011.

Selected_Quarterly_Financial_D

Selected Quarterly Financial Data	12 Months Ended
	Dec. 31, 2014
Selected Quarterly Financial Data [Abstract]
Selected Quarterly Financial Data	11.  Selected Quarterly Financial Data (Unaudited) (in thousands, except per share data)
			Quarters Ended
			31-Mar		30-Jun		30-Sep		31-Dec
		2014
		Total revenue	$	—	$	—	$	—	$	—
		Net loss	$	-3,450	$	-3,246	$	-3,534	$	-2,156
		Basic and diluted net loss per share	$	-0.08	$	-0.07	$	-0.08	$	-0.05
		2013
		Total revenue	$	1,958	$	1,959	$	1,958	$	35,244
		Net income (loss)	$	-408	$	-301	$	-762	$	33,015
		Basic net income (loss) per share	$	-0.01	$	-0.01	$	-0.02	$	0.73
		Diluted net income (loss) per share	$	-0.01	$	-0.01	$	-0.02	$	0.72
		2012
		Total revenue	$	2,973	$	2,724	$	2,725	$	2,468
		Net income (loss)	$	30	$	-130	$	-1,550	$	-1,796
		Basic and diluted net income (loss) per share	$	0.00	$	0	$	-0.03	$	-0.04

Summary_Of_Significant_Account1

Summary Of Significant Accounting Policies (Policy)	12 Months Ended
	Dec. 31, 2014
Summary Of Significant Accounting Policies [Abstract]
Use Of Estimates	Use of Estimates
	The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires that management make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of revenue earned and expenses incurred during the reporting period. Actual results could differ from those estimates.
Revenue Recognition And Deferred Program Fee Revenue	Revenue Recognition and Deferred Program Fee Revenue
	Revenue is recognized when there is persuasive evidence that an arrangement exists, delivery has occurred, the price is fixed or determinable, and collection is reasonably assured.
	We have recognized program fee revenue, collaboration revenue and milestone revenue under the Collaboration Agreement and License Agreement with Pfizer, or the Pfizer Agreements. Program fee revenue was derived from upfront payments from Pfizer. Through the end of the third quarter of 2013, these payments were recognized from receipt ratably over our estimate of the development period under the Pfizer Agreements. In October 2013, we and Pfizer amended the Pfizer Agreements, we no longer had any substantive responsibilities for development activities under the Pfizer Agreements and, during the fourth quarter of 2013, we recognized all remaining deferred program fee revenue as program fee revenue.
	Collaboration revenues from reimbursement of development expenses was generally recognized when Pfizer completed its review of the expenses invoiced to them.
	We recognized milestone payments from Pfizer as revenue when we achieved the underlying developmental milestone as the milestone payments were not dependent upon any other future activities or achievement of any other future milestones and the achievement of each of the developmental milestones were substantively at risk and contingent at the effective date of the collaboration. Substantial effort was involved in achieving each of the developmental milestones. These milestones represented the culmination of discrete earnings processes and the amount of each milestone payment was reasonable in relation with the level of effort associated with the achievement of the milestone. Each milestone payment was non-refundable and non-creditable when made. Research and development services provided under the Pfizer Agreements were priced at fair value based upon the reimbursement of expenses incurred pursuant to the Pfizer Agreements.
Cash, Cash Equivalents And Concentration Of Credit Risk	Cash, Cash Equivalents and Concentration of Credit Risk
	We consider all highly liquid financial instruments with original maturities of three months or less to be cash equivalents. Cash and cash equivalents are maintained at two financial institutions and in money market funds. We believe the financial risks associated with these instruments are minimal. We have not incurred material losses from our investments in these securities.
Marketable Securities And Fair Value Measurements	Marketable Securities and Fair Value Measurements
	We invest in interest-bearing marketable securities, generally consisting of corporate and government securities. We may elect to sell these investments before they mature. Therefore, we hold these investments as “available for sale” and include these investments in our balance sheets as current assets, even though the contractual maturity of a particular investment may be beyond one year. We report our marketable securities at fair value, which may include unrealized gains and losses. Our unrealized gains and losses on investments are recorded as a separate component of stockholders’ equity as accumulated other comprehensive income or loss. We recognize all realized gains and losses on our available-for-sale securities in interest income in the accompanying statement of operations on a specific identification basis. Our marketable securities are maintained at one financial institution and are governed by our investment policy as approved by our Board of Directors.
	To date we have not recorded any impairment charges on marketable securities related to other-than-temporary declines in market value. We would recognize an impairment charge when the decline in the estimated fair value of a marketable security below the amortized cost is determined to be other-than-temporary. We consider various factors in determining whether to recognize an impairment charge, including the duration of time and the severity to which the fair value has been less than our amortized cost, any adverse changes in the investees’ financial condition and our intent to sell or whether it is more likely than not that we would be required to sell the marketable security before its anticipated recovery.
	We measure our cash equivalents and marketable securities at fair value on a recurring basis and have significant observable inputs where there are identical or comparable assets in the market to use in establishing our fair value measurements. We use significant observable inputs that include but are not limited to benchmark yields, reported trades, broker/dealer quotes and issuer spreads. We consider these inputs to be Level 2 inputs. Generally, the types of instruments we invest in are not traded on a market such as the NASDAQ Global Market, which we would consider to be Level 1 inputs. We do not have any investments that would require inputs considered to be Level 3. We use the bid price to establish fair value.
Business Segments	Business Segments
	We report segment information based on how we internally evaluate the operating performance of our business units, or segments. Our operations are confined to one business segment: the development of novel drugs.
Stock-Based Compensation	Stock-based Compensation
	We recognize non-cash expense in the statement of operations for the fair value of all share-based payments, including grants of employee stock options and other share based awards. For stock options, we use the Black-Scholes option valuation model and the single-option award approach and straight-line attribution method. Using this approach, the compensation expense is amortized on a straight-line basis over the vesting period of each respective stock option, generally four years.
	We have granted share-based awards that vest upon achievement of certain performance criteria, or Performance Awards. The value of these awards is the product of the number of shares of our common stock to be issued under the award multiplied by the fair market value of a share of our common stock on the date of grant. These awards include future performance conditions. We estimate an implicit service period for achieving these performance conditions. Performance Awards vest and common stock is issued on achieving performance conditions. We recognize non-cash stock-based compensation expense for Performance Awards when we conclude that achieving a performance condition is probable. We periodically review and update as appropriate our estimates of the implicit service periods and the likelihood of achieving the performance conditions.
Net Loss Per Share
	Net Loss per Share
	Basic net loss per share is computed on the basis of the weighted-average number of common shares outstanding for the reporting period. Diluted net loss per share is computed on the basis of the weighted-average number of common shares outstanding plus dilutive potential common shares outstanding using the treasury-stock method. Potential dilutive common shares consist of outstanding stock options and warrants. The numerators and denominators in the calculation of basic and diluted net loss per share were as follows (in thousands):
		Years ended December 31,
		2014		2013		2012
	Numerator:
	Net income (loss)	$	-12,386	$	31,544	$	-3,446
	Denominator:
	Weighted-average shares used to compute basic net income (loss) per share		45,269		45,007		44,753
	Effect of dilutive securities - Dilution from employee stock plans		—		201		—
	Weighted-average shares used to compute diluted net income (loss) per share		45,269		45,208	—	44,753
	Net income (loss) per share - Basic	$	-0.27	$	0.70	$	-0.08
	Net income (loss) per share - Diluted	$	-0.27	$	0.70	$	-0.08
	We excluded weighted options outstanding to purchase common stock of 10.6 million for 2014, 13.5 million for 2013 and 13.2 million for 2012 from the calculation of diluted net loss per share because the effect of including these shares in this calculation would be anti-dilutive.
Income Taxes	Income Taxes
	We make estimates and judgments in determining the need for a provision for income taxes, including the estimation of our taxable income or loss for each full fiscal year. We have accumulated significant deferred tax assets. Deferred income taxes reflect the tax effects of net operating loss and tax credit carryovers and temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Realization of certain deferred tax assets is dependent upon future earnings, if any. We are uncertain about the timing and amount of any future earnings. Accordingly, we offset these net deferred tax assets with a valuation allowance. We may in the future determine that our deferred tax assets will likely be realized, in which case we will reduce our valuation allowance in the quarter in which such determination is made. If the valuation allowance is reduced, we may recognize a benefit from income taxes in our statement of operations in that period. We classify interest and penalties recognized related to uncertain tax positions as interest expense.
Recent Accounting Pronouncements	Recent Accounting Pronouncements
	We reviewed recently issued accounting pronouncements and plan to adopt those that are applicable to us. We do not expect the adoption of these pronouncements to have a material impact on our financial position, results of operations or cash flows.

Summary_Of_Significant_Account2

Summary Of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2014
Summary Of Significant Accounting Policies [Abstract]
Numerators And Denominators In The Calculation Of Basic And Diluted Net Loss Per Share
		Years ended December 31,
		2014		2013		2012
	Numerator:
	Net income (loss)	$	-12,386	$	31,544	$	-3,446
	Denominator:
	Weighted-average shares used to compute basic net income (loss) per share		45,269		45,007		44,753
	Effect of dilutive securities - Dilution from employee stock plans		—		201		—
	Weighted-average shares used to compute diluted net income (loss) per share		45,269		45,208	—	44,753
	Net income (loss) per share - Basic	$	-0.27	$	0.70	$	-0.08
	Net income (loss) per share - Diluted	$	-0.27	$	0.70	$	-0.08

Cash_And_Cash_Equivalents_And_1

Cash And Cash Equivalents And Marketable Securities (Tables)	12 Months Ended
	Dec. 31, 2014
Cash And Cash Equivalents And Marketable Securities [Abstract]
Cash, Cash Equivalents And Marketable Securities
			Cash, Cash Equivalents and Marketable Securities
			Amortized Cost		Unrealized Gains		Unrealized Losses		Estimated Fair Value		Accrued Interest		Total Value
		31-Dec-14
		Cash	$	295	$	—	$	—	$	295	$	—	$	295
		Cash equivalents		34,805		—		—		34,805		—		34,805
		Commercial paper		4,848		1		—		4,849		—		4,849
		Corporate securities		631		—		—		631		10		641
			$	40,579	$	1	$	—	$	40,580	$	10	$	40,590
		Reported as:
		Cash and cash equivalents	$	40,579	$	1	$	—	$	40,580	$	10	$	40,590
			$	40,579	$	1	$	—	$	40,580	$	10	$	40,590
		Maturities:
		Matures in one year or less	$	40,579	$	1	$	—	$	40,580	$	10	$	40,590
		Matures one to three years		—		—		—		—		—		—
			$	40,579	$	1	$	—	$	40,580	$	10	$	40,590
		31-Dec-13
		Cash and cash equivalents	$	48,587	$	1	$	—	$	48,588	$	—	$	48,588
		Commercial paper		1,250		—		—		1,250		—		1,250
			$	49,837	$	1	$	—	$	49,838	$	—	$	49,838
		Reported as:
		Cash and cash equivalents	$	48,587	$	1	$	—	$	48,588	$	—	$	48,588
		Marketable securities		1,250		—		—		1,250		—		1,250
			$	49,837	$	1	$	—	$	49,838	$	—	$	49,838
		Maturities:
		Matures in one year or less	$	49,837	$	1	$	—	$	49,838	$	—	$	49,838
		Matures one to three years		—		—		—		—		—		—
			$	49,837	$	1	$	—	$	49,838	$	—	$	49,838
Assets Measured At Fair Value On Recurring Basis
			Level 1		Level 2		Level 3		Total
		31-Dec-14
		Cash and cash equivalents	$	35,100	$	—	$	—	$	35,100
		Commercial paper		—		4,849		—		4,849
		Corporate securities		—		641		—		641
			$	35,100	$	5,490	$	—	$	40,590
		31-Dec-13
		Cash and cash equivalents	$	48,588	$	—	$	—	$	48,588
		Commercial paper		—		1,250		—		1,250
			$	48,588	$	1,250	$	—	$	49,838

Stockholders_Equity_And_StockB1

Stockholders' Equity And Stock-Based Compensation (Tables)	12 Months Ended
	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Option Activity
			Number of Options		Weighted Average Exercise Price		Weighted Average Remaining Contractual Term		Aggregate Intrinsic Value
							In years			In millions
		Outstanding as of December 31, 2013	16,133,893		$	4.06	5		$	16.3
		Granted	3,525,000		$	3.45
		Exercised	-1,245,750		$	4.52
		Cancelled	-499,961		$	3.84
		Outstanding as of December 31, 2014	17,913,182		$	3.92	5		$	0.5
		Vested and expected to vest at December 31, 2014	17,913,182		$	3.92	5		$	0.5
		Exercisable at December 31, 2014	13,132,300		$	4.17	3.5		$	0
Information About Stock Options Outstanding
							Options outstanding						Options exercisable
									Weighted
									average		Weighted			Weighted
							Number of		remaining		average		Number of	average
		Range of exercise prices					outstanding		contractual		exercise		vested	exercise
		From			To		options		life (in years)		price		options	price
		$	1.72		$	2.58	4,582,503		7.5		$	2.21	2,006,262	$	2.51
		$	2.8		$	3.41	4,370,573		4.1		$	3.22	3,832,495	$	3.23
		$	3.58		$	4.82	4,320,069		3.2		$	4.59	4,059,038	$	4.59
		$	4.88		$	7	3,695,188		5		$	5.13	2,387,711	$	5.15
		$	7.65		$	7.65	944,849		5.5		$	7.65	846,794	$	7.65
							17,913,182		5		$	3.92	13,132,300	$	4.17
Weighted Average Fair Value Of Options Granted
		2014		2013		2012
	Volatility	68% to 74%		58% to 64%		56% to 64%
	Risk-free interest rates	1% to 2%		1% to 2%		1%
	Expected life of option	7 years		7 years		6 years
	Dividend yield	zero		zero		zero
	Forfeiture rate	zero		zero		7%
	Weighted average fair value of stock options granted	$2.32		$1.54		$1.70
Summary Of Non-Cash Stock-Based Compenstion
		Years ended December 31,
		2014			2013		2012
	Research and development	$	1,624		$	1,349	$	3,164
	General and administrative		2,137			1,752		3,446
		$	3,761		$	3,101	$	6,610
Performance Awards [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Option Activity
									Number of Performance Awards
	Outstanding as of December 31, 2013								3,250,065
	Granted								885,000
	Cancelled								-2,245,600
	Outstanding as of December 31, 2014								1,889,465

Income_Taxes_Tables

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2014
Income Taxes [Abstract]
Schedule Of Effective Income Tax Rate Reconciliation
						2013
	Tax at U.S. statutory tax rate of 34%					$	10,725
	State taxes						-73
	Equity-based compensation						844
	Research credits						-81
	Other						-242
	Change in valuation allowance						-11,246
	Benefit from income taxes					$	-73
Schedule Of Deferred Tax Assets And Valuation Allowance
		December 31,
		2014		2013
	Deferred tax assets:
	Net operating loss carryforwards	$	13,800	$	10,200
	Stock-related compensation		10,900		11,100
	Research & development credit carryforwards		5,800		5,700
	Other		300		600
			30,800		27,600
	Valuation allowance		-30,800		-27,600
		$	—	$	—
Schedule Of Unrecognized Tax Benefits
			2014		2013
	Beginning balance	$	3,800	$	5,200
	Additions based on tax positions related to the current year		100		100
	Lapse of applicable statute of limitations		—		-600
	Reductions for tax positions related to prior years		—		-900
	Ending balance	$	3,900	$	3,800

Selected_Quarterly_Financial_D1

Selected Quarterly Financial Data (Tables)	12 Months Ended
	Dec. 31, 2014
Selected Quarterly Financial Data [Abstract]
Quarterly Financial Information
			Quarters Ended
			31-Mar		30-Jun		30-Sep		31-Dec
		2014
		Total revenue	$	—	$	—	$	—	$	—
		Net loss	$	-3,450	$	-3,246	$	-3,534	$	-2,156
		Basic and diluted net loss per share	$	-0.08	$	-0.07	$	-0.08	$	-0.05
		2013
		Total revenue	$	1,958	$	1,959	$	1,958	$	35,244
		Net income (loss)	$	-408	$	-301	$	-762	$	33,015
		Basic net income (loss) per share	$	-0.01	$	-0.01	$	-0.02	$	0.73
		Diluted net income (loss) per share	$	-0.01	$	-0.01	$	-0.02	$	0.72
		2012
		Total revenue	$	2,973	$	2,724	$	2,725	$	2,468
		Net income (loss)	$	30	$	-130	$	-1,550	$	-1,796
		Basic and diluted net income (loss) per share	$	0.00	$	0	$	-0.03	$	-0.04

Summary_Of_Significant_Account3

Summary Of Significant Accounting Policies (Narrative) (Details)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
	segment
	item
Summary Of Significant Accounting Policies [Abstract]
Number of financial institutions that maintain cash and cash equivalents	2
Contractual maturity of a particular investment	1 year
Number of financial institutions that maintain marketable securities	1
Number of business segments	1
Vesting period of stock options	4 years
Anti-dilutive shares excluded from computation of diluted net loss per share	10.6	13.5	13.2

Summary_Of_Significant_Account4

Summary Of Significant Accounting Policies (Numerators And Denominators In The Calculation Of Basic And Diluted Net Loss Per Share) (Details) (USD $)	3 Months Ended				12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Numerator:
Net income (loss)					($12,386)	$31,544	($3,446)
Denominator:
Weighted-average shares used to compute basic net income (loss) per share					45,269	45,007	44,753
Effect of dilutive securities - Dilution from employee stock plans						201
Weighted-average shares used to compute diluted net income (loss) per share					45,269	45,208	44,753
Net income (loss) per share - Basic	$0.73	($0.02)	($0.01)	($0.01)	($0.27)	$0.70	($0.08)
Net income (loss) per share - Diluted	$0.72	($0.02)	($0.01)	($0.01)	($0.27)	$0.70	($0.08)

Collaboration_Agreements_Detai

Collaboration Agreements (Details) (USD $)	1 Months Ended	12 Months Ended		85 Months Ended
	Jul. 31, 2010	Dec. 31, 2013	Dec. 31, 2012	Nov. 30, 2012
Collaboration Agreements [Abstract]
Upfront cash payment	$5,000,000			$150,000,000
Program fee revenue		41,119,000	10,641,000
Collaboration revenue			$249,000

Cash_And_Cash_Equivalents_And_2

Cash And Cash Equivalents And Marketable Securities (Cash, Cash Equivalents And Marketable Securities) (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
In Thousands, unless otherwise specified
Schedule of Available-for-sale Securities [Line Items]
Cash and cash equivalents	$40,590	$48,588	$49,355	$73,144
Cash and cash equivalents, Short Term Investment, Amortized Cost	40,579	49,837
Cash and cash equivalents, Short Term Investment Unrealized Gains	1	1
Cash and cash equivalents, Short Term Investment Unrealized Losses
Accrued Interest	10
Estimated Fair Value, Marketable securities		1,250
Cash and cash equivalents, Short Term Investment, Fair Value	40,590	49,838
Marketable Securities [Member]
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale securities, Amortized Cost Basis		1,250
Available-for-sale securities, Gross Unrealized Losses
Accrued Interest
Estimated Fair Value, Marketable securities		1,250
Cash [Member]
Schedule of Available-for-sale Securities [Line Items]
Cash	295
Available-for-sale securities, Gross Unrealized Losses
Accrued Interest
Cash and cash equivalents, Fair Value	295
Cash Equivalents [Member]
Schedule of Available-for-sale Securities [Line Items]
Cash equivalents	34,805
Available-for-sale securities, Gross Unrealized Losses
Accrued Interest
Cash and cash equivalents, Fair Value	34,805
Cash And Cash Equivalents [Member]
Schedule of Available-for-sale Securities [Line Items]
Cash and cash equivalents		48,587
Available-for-sale securities, Gross Unrealized Gains		1
Available-for-sale securities, Gross Unrealized Losses
Accrued Interest
Cash and cash equivalents, Fair Value		48,588
Commercial Paper [Member]
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale securities, Amortized Cost Basis	4,848	1,250
Available-for-sale securities, Gross Unrealized Gains	1
Available-for-sale securities, Gross Unrealized Losses
Accrued Interest
Estimated Fair Value, Marketable securities	4,849	1,250
Corporate Securities [Member]
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale securities, Amortized Cost Basis	631
Available-for-sale securities, Gross Unrealized Losses
Accrued Interest	10
Estimated Fair Value, Marketable securities	641
Cash And Cash Equivalents, Reported Value [Member]
Schedule of Available-for-sale Securities [Line Items]
Cash and cash equivalents	40,579	48,587
Available-for-sale securities, Gross Unrealized Gains	1	1
Available-for-sale securities, Gross Unrealized Losses
Accrued Interest	10
Cash and cash equivalents, Fair Value	40,590	48,588
Matures In One Year Or Less [Member]
Schedule of Available-for-sale Securities [Line Items]
Cash and cash equivalents, Short Term Investment, Amortized Cost	40,579	49,837
Available-for-sale securities, Gross Unrealized Gains	1	1
Available-for-sale securities, Gross Unrealized Losses
Accrued Interest	10
Cash and cash equivalents, Short Term Investment, Fair Value	40,590	49,838
Matures One To Three Years [Member]
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale securities, Gross Unrealized Losses
Accrued Interest
Estimated Fair Value, Fair Value Disclosure [Member]
Schedule of Available-for-sale Securities [Line Items]
Cash and cash equivalents, Short Term Investment, Fair Value	40,580	49,838
Estimated Fair Value, Fair Value Disclosure [Member] | Marketable Securities [Member]
Schedule of Available-for-sale Securities [Line Items]
Estimated Fair Value, Marketable securities		1,250
Estimated Fair Value, Fair Value Disclosure [Member] | Cash [Member]
Schedule of Available-for-sale Securities [Line Items]
Cash and cash equivalents, Fair Value	295
Estimated Fair Value, Fair Value Disclosure [Member] | Cash Equivalents [Member]
Schedule of Available-for-sale Securities [Line Items]
Cash and cash equivalents, Fair Value	34,805
Estimated Fair Value, Fair Value Disclosure [Member] | Cash And Cash Equivalents [Member]
Schedule of Available-for-sale Securities [Line Items]
Cash and cash equivalents, Fair Value		48,588
Estimated Fair Value, Fair Value Disclosure [Member] | Commercial Paper [Member]
Schedule of Available-for-sale Securities [Line Items]
Estimated Fair Value, Marketable securities	4,849	1,250
Estimated Fair Value, Fair Value Disclosure [Member] | Corporate Securities [Member]
Schedule of Available-for-sale Securities [Line Items]
Estimated Fair Value, Marketable securities	631
Estimated Fair Value, Fair Value Disclosure [Member] | Cash And Cash Equivalents, Reported Value [Member]
Schedule of Available-for-sale Securities [Line Items]
Cash and cash equivalents, Fair Value	40,580	48,588
Estimated Fair Value, Fair Value Disclosure [Member] | Matures In One Year Or Less [Member]
Schedule of Available-for-sale Securities [Line Items]
Cash and cash equivalents, Short Term Investment, Fair Value	$40,580	$49,838

Cash_And_Cash_Equivalents_And_3

Cash And Cash Equivalents And Marketable Securities (Assets Measured At Fair Value On Recurring Basis) (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets measured at fair value	$40,590	$49,838
Cash [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets measured at fair value	35,100
Cash And Cash Equivalents [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets measured at fair value		48,588
Commercial Paper [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets measured at fair value	4,849	1,250
Corporate Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets measured at fair value	641
Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets measured at fair value	35,100	48,588
Level 1 [Member] | Cash [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets measured at fair value	35,100
Level 1 [Member] | Cash And Cash Equivalents [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets measured at fair value		48,588
Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets measured at fair value	5,490	1,250
Level 2 [Member] | Commercial Paper [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets measured at fair value	4,849	1,250
Level 2 [Member] | Corporate Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets measured at fair value	641
Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets measured at fair value
Level 3 [Member] | Cash [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets measured at fair value
Level 3 [Member] | Cash And Cash Equivalents [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets measured at fair value
Level 3 [Member] | Commercial Paper [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets measured at fair value
Level 3 [Member] | Corporate Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets measured at fair value

Property_And_Equipment_Details

Property And Equipment (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2012	Dec. 31, 2013
Property, Plant and Equipment [Line Items]
Accumulated depreciation	$600,000		$600,000
Depreciation and amortization expense	15,000	122,000
Furniture And Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, purchase value	$700,000		$600,000

Stockholders_Equity_And_StockB2

Stockholders' Equity And Stock-Based Compensation (Narrative) (Details) (USD $)	12 Months Ended
In Millions, except Share data, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Dividend yield	0.00%	0.00%	0.00%
2008 Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares reserved for issuance	4,100,000
Common stock shares granted to outside directors	50,000
Expiration period of stock options granted	10 years
Fair market value percent	100.00%
Options exercisable percentage	25.00%
Pre-tax intrinsic value of options exercised	0.9	0.2
Compensation costs prior to forfeiture	10.3
Weighted average remaining recognition period	3 years
2000 Employee Stock Purchase Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Fair market value percent	85.00%
Performance Awards [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Additional stock compensation expense	5.3
Series A Preferred Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price, Preferred Stock	40

Stockholders_Equity_And_StockB3

Stockholders' Equity And Stock-Based Compensation (Stock Option Activity) (Details) (USD $)	12 Months Ended
In Millions, except Share data, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Beginning Balance, Number of Options, Outstanding	16,133,893
Number of Options, Granted	3,525,000
Number of Options, Exercised	-1,245,750
Number of Options, Cancelled	-499,961
Ending Balance, Number of Options, Outstanding	17,913,182	16,133,893
Number of Options, Vested and expected to vest	17,913,182
Number of Options, Exercisable	13,132,300
Beginning Balance, Weighted Average Exercise Price	$4.06
Weighted Average Exercise Price, Granted	$3.45
Weighted Average Exercise Price, Exercised	$4.52
Weighted Average Exercise Price, Cancelled	$3.84
Ending Balance, Weighted Average Exercise Price	$3.92	$4.06
Weighted Average Exercise Price, Vested and expected to vest	$3.92
Weighted Average Exercise Price, Exercisable	$4.17
Beginning of year, Weighted Average Remaining Contractual Term	5 years	5 years
End of year, Weighted Average Remaining Contractual Term	5 years	5 years
Weighted Average Remaining Contractual Term, Vested and expected to vest	5 years
Weighted Average Remaining Contractual Term, Exercisable	3 years 6 months
Beginning Balance, Aggregate Intrinsic Value	$16.30
Ending Balance, Aggregate Intrinsic Value	0.5	16.3
Aggregate Intrinsic Value, Vested and expected to vest	0.5
Aggregate Intrinsic Value, Exercisable	$0
Performance Awards [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding as of December 31, 2013	3,250,065
Granted	885,000
Cancelled	-2,245,600
Outstanding as of December 31, 2014	1,889,465

Stockholders_Equity_And_StockB4

Stockholders' Equity And Stock-Based Compensation (Information About Stock Options Outstanding) (Details) (USD $)	12 Months Ended
	Dec. 31, 2014
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Stock options, outstanding	17,913,182
Weighted average remaining contractual life	5 years
Weighted average exercise price, Options outstanding	$3.92
Number of vested options, Options exercisable	13,132,300
Weighted average exercise price, Options exercisable	$4.17
$1.72 - $2.58 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of exercise prices, Minimum	$1.72
Range of exercise prices, Maximum	$2.58
Stock options, outstanding	4,582,503
Weighted average remaining contractual life	7 years 6 months
Weighted average exercise price, Options outstanding	$2.21
Number of vested options, Options exercisable	2,006,262
Weighted average exercise price, Options exercisable	$2.51
$2.80 - $3.41 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of exercise prices, Minimum	$2.80
Range of exercise prices, Maximum	$3.41
Stock options, outstanding	4,370,573
Weighted average remaining contractual life	4 years 1 month 6 days
Weighted average exercise price, Options outstanding	$3.22
Number of vested options, Options exercisable	3,832,495
Weighted average exercise price, Options exercisable	$3.23
$3.58 - $4.82 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of exercise prices, Minimum	$3.58
Range of exercise prices, Maximum	$4.82
Stock options, outstanding	4,320,069
Weighted average remaining contractual life	3 years 2 months 12 days
Weighted average exercise price, Options outstanding	$4.59
Number of vested options, Options exercisable	4,059,038
Weighted average exercise price, Options exercisable	$4.59
$4.88 - $7.00 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of exercise prices, Minimum	$4.88
Range of exercise prices, Maximum	$7
Stock options, outstanding	3,695,188
Weighted average remaining contractual life	5 years
Weighted average exercise price, Options outstanding	$5.13
Number of vested options, Options exercisable	2,387,711
Weighted average exercise price, Options exercisable	$5.15
$7.65 - $7.65 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of exercise prices, Minimum	$7.65
Range of exercise prices, Maximum	$7.65
Stock options, outstanding	944,849
Weighted average remaining contractual life	5 years 6 months
Weighted average exercise price, Options outstanding	$7.65
Number of vested options, Options exercisable	846,794
Weighted average exercise price, Options exercisable	$7.65

Stockholders_Equity_And_StockB5

Stockholders' Equity And Stock-Based Compensation (Weighted Average Fair Value Of Options Granted) (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Stockholders' Equity And Stock-Based Compensation [Abstract]
Volatility, Minimum	68.00%	58.00%	56.00%
Volatility, Maximum	74.00%	64.00%	64.00%
Risk-free interest rates			1.00%
Risk-free interest rates, Minimum	1.00%	1.00%
Risk-free interest rates, Maximum	2.00%	2.00%
Expected life of option	7 years	7 years	6 years
Dividend yield	0.00%	0.00%	0.00%
Forfeiture rate	0.00%	0.00%	7.00%
Weighted average fair value of stock options granted	$2.32	$1.54	$1.70

Stockholders_Equity_And_StockB6

Stockholders' Equity And Stock-Based Compensation (Summary Of Non-Cash Stock-Based Compenstion) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Stock-Based Compensation [Line Items]
Share Based Compensation	$3,761	$3,101	$6,610
Research And Development [Member]
Stock-Based Compensation [Line Items]
Share Based Compensation	1,624	1,349	3,164
General And Administrative [Member]
Stock-Based Compensation [Line Items]
Share Based Compensation	$2,137	$1,752	$3,446

Income_Taxes_Narrative_Details

Income Taxes (Narrative) (Details) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Operating Loss Carryforwards [Line Items]
Valuation allowance increase (decrease)	$3.20	($14.60)
Part of valuation allowance as tax benefits associated with stock option transactions	2.5
Federal [Member]
Operating Loss Carryforwards [Line Items]
Pre-tax net operating loss carryforwards	43
Federal research and development tax credits	$9.70
Federal [Member] | Minimum [Member]
Operating Loss Carryforwards [Line Items]
Expiration date of pre-tax net operating loss carryforwards	1-Jan-29
Expiration date of federal research and development tax credits	1-Jan-23
Federal [Member] | Maximum [Member]
Operating Loss Carryforwards [Line Items]
Expiration date of pre-tax net operating loss carryforwards	31-Dec-34
Expiration date of federal research and development tax credits	31-Dec-34

Income_Taxes_Schedule_Of_Effec

Income Taxes (Schedule Of Effective Income Tax Rate Reconciliation) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013
Income Taxes [Abstract]
Tax at U.S. statutory tax rate of 34%	$10,725
State taxes	-73
Equity-based compensation	844
Research credits	-81
Other	-242
Change in valuation allowance	-11,246
Benefit from income taxes	($73)
U.S. statutory tax rate	34.00%

Income_Taxes_Schedule_Of_Defer

Income Taxes (Schedule Of Deferred Tax Assets And Valuation Allowance) (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Income Taxes [Abstract]
Net operating loss carryforwards	$13,800	$10,200
Stock-related compensation	10,900	11,100
Research & development credit carryforwards	5,800	5,700
Other	300	600
Total deferred tax assets	30,800	27,600
Valuation allowance	-30,800	-27,600
Net deferred tax assets

Income_Taxes_Schedule_Of_Unrec

Income Taxes (Schedule Of Unrecognized Tax Benefits) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Income Taxes [Abstract]
Beginning balance	$3,800	$5,200
Additions based on tax positions related to the current year	100	100
Lapse of applicable statute of limitations		-600
Reductions for tax positions related to prior years		-900
Ending Balance	$3,900	$3,800

Leases_And_Commitments_Narrati

Leases And Commitments (Narrative) (Details) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
	sqft
Leases And Commitments [Line Items]
Office space	6,000
Rent expense	$0.10	$0.10	$0.10
Austin, TX [Member]
Leases And Commitments [Line Items]
Operating lease expiration year	2017-01

Leases_And_Commitments_Future_

Leases And Commitments (Future Minimum Lease Payments) (Details) (USD $)	Dec. 31, 2014
In Thousands, unless otherwise specified
Leases And Commitments [Abstract]
Minimum lease payments, 2015	$143
Minimum lease payments, 2016	146
Minimum lease payments, 2017	147
Total	$436

Selected_Quarterly_Financial_D2

Selected Quarterly Financial Data (Details) (USD $)	3 Months Ended												12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Selected Quarterly Financial Data [Abstract]
Total revenue					$35,244	$1,958	$1,959	$1,958	$2,468	$2,725	$2,724	$2,973		$41,119	$10,890
Net income (loss)	($2,156)	($3,534)	($3,246)	($3,450)	$33,015	($762)	($301)	($408)	($1,796)	($1,550)	($130)	$30	($12,386)	$31,471	($3,446)
Net income (loss) per share - Basic					$0.73	($0.02)	($0.01)	($0.01)					($0.27)	$0.70	($0.08)
Net income (loss) per share - Diluted					$0.72	($0.02)	($0.01)	($0.01)					($0.27)	$0.70	($0.08)
Basic and diluted net income (loss) per share	($0.05)	($0.08)	($0.07)	($0.08)					($0.04)	($0.03)	$0	$0